TRADES
Latest Trades
112
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 24 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 51,689 0.0160
ARKG 21 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 164,710 0.0526
ARKG 20 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 39,424 0.0127
ARKG 19 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 39,992 0.0124
ARKK 5 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 188,200 0.0160
ARKG 4 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 51,500 0.0141
ARKG 3 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 13,200 0.0039
ARKG 31 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 23,900 0.0067
ARKG 30 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 100 0.0000
ARKG 29 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 105,770 0.0279
ARKK 28 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 20,000 0.0016
ARKK 27 Dec 2021 Sell SGFY SIGNIFY HEALTH INC 20,321 0.0017
ARKG 7 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 160,234 0.0474
ARKK 7 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 313,766 0.0289
ARKK 6 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 20,402 0.0000
ARKK 3 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 52,700 0.0000
ARKK 2 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 9,550 0.0008
ARKK 30 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 72,300 0.0100
ARKG 29 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 56,672 0.0141
ARKG 26 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 22,600 0.0100
ARKG 24 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 79,400 0.0195
ARKG 15 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 159,698 0.0374
ARKK 12 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 230,000 0.0183
ARKK 11 Nov 2021 Buy SGFY SIGNIFY HEALTH INC 258,910 0.0209
ARKK 8 Oct 2021 Buy SGFY SIGNIFY HEALTH INC 290,491 0.0260
ARKK 7 Oct 2021 Buy SGFY SIGNIFY HEALTH INC 413,895 0.0400
ARKK 6 Oct 2021 Buy SGFY SIGNIFY HEALTH INC 325,861 0.0300
ARKG 5 Oct 2021 Buy SGFY SIGNIFY HEALTH INC 391,069 0.1008
ARKK 5 Oct 2021 Buy SGFY SIGNIFY HEALTH INC 358,048 0.0333
ARKK 29 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 687,469 0.0659
ARKG 28 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 402,747 0.1039
ARKK 28 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 390,775 0.0357
ARKK 27 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 123,857 0.0115
ARKK 24 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 336,780 0.0310
ARKG 23 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 500,056 0.1277
ARKK 23 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 830,777 0.0777
ARKG 22 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 663,604 0.1913
ARKK 22 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 972,792 0.0994
ARKK 21 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 317,206 0.0355
ARKK 20 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 202,238 0.0213
ARKK 14 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 618,151 0.0700
ARKK 13 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 250,366 0.0300
ARKK 1 Sep 2021 Buy SGFY SIGNIFY HEALTH INC 189,960 0.0225
ARKK 31 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 92,717 0.0108
ARKK 30 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 418,845 0.0496
ARKK 27 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 190,400 0.0230
ARKK 26 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 178,955 0.0209
ARKK 25 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 206,099 0.0242
ARKK 24 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 205,551 0.0247
ARKK 23 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 116,171 0.0143
ARKK 20 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 18,900 0.0023
ARKK 19 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 149,483 0.0177
ARKK 18 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 120,721 0.0143
ARKK 17 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 290,303 0.0326
ARKG 16 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 784,785 0.2394
ARKK 16 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 228,429 0.0263
ARKK 13 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 955,467 0.1094
ARKK 12 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 153,790 0.0170
ARKK 11 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 807,917 0.0862
ARKG 10 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 308,074 0.0944
ARKG 9 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 30,490 0.0096
ARKG 6 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 269,965 0.0823
ARKG 5 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 21,100 0.0066
ARKG 4 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 484,603 0.1523
ARKG 3 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 31,587 0.0097
ARKG 2 Aug 2021 Buy SGFY SIGNIFY HEALTH INC 102,356 0.0314
ARKG 30 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 35,124 0.0106
ARKG 28 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 67,255 0.0212
ARKG 27 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 226,500 0.0696
ARKG 26 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 99,700 0.0311
ARKG 23 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 198,270 0.0630
ARKG 22 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 19,156 0.0060
ARKG 21 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 9,907 0.0032
ARKG 20 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 16,800 0.0055
ARKG 19 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 74,630 0.0253
ARKG 16 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 52,820 0.0172
ARKG 15 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 36,732 0.0115
ARKG 14 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 99,674 0.0308
ARKG 13 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 123,187 0.0386
ARKG 12 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 9,412 0.0030
ARKG 8 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 90,214 0.0290
ARKG 7 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 53,916 0.0166
ARKG 6 Jul 2021 Buy SGFY SIGNIFY HEALTH INC 171,555 0.0521
ARKG 3 Jun 2021 Buy SGFY SIGNIFY HEALTH INC 32,322 0.0099
ARKG 2 Jun 2021 Buy SGFY SIGNIFY HEALTH INC 129,777 0.0395
ARKG 1 Jun 2021 Buy SGFY SIGNIFY HEALTH INC 340,872 0.1031
ARKG 24 May 2021 Buy SGFY SIGNIFY HEALTH INC 24,793 0.0082
ARKG 21 May 2021 Buy SGFY SIGNIFY HEALTH INC 832,666 0.2788
ARKG 20 May 2021 Buy SGFY SIGNIFY HEALTH INC 139,900 0.0464
ARKG 19 May 2021 Buy SGFY SIGNIFY HEALTH INC 23,140 0.0078
ARKG 18 May 2021 Buy SGFY SIGNIFY HEALTH INC 27,803 0.0093
ARKG 17 May 2021 Buy SGFY SIGNIFY HEALTH INC 80,316 0.0269
ARKG 14 May 2021 Buy SGFY SIGNIFY HEALTH INC 202,015 0.0680
ARKG 13 May 2021 Buy SGFY SIGNIFY HEALTH INC 112,058 0.0377
ARKG 12 May 2021 Buy SGFY SIGNIFY HEALTH INC 57,509 0.0192
ARKG 8 Apr 2021 Buy SGFY SIGNIFY HEALTH INC 25,851 0.0072
ARKG 7 Apr 2021 Buy SGFY SIGNIFY HEALTH INC 182,193 0.0508
ARKG 6 Apr 2021 Buy SGFY SIGNIFY HEALTH INC 91,624 0.0262
ARKG 5 Apr 2021 Buy SGFY SIGNIFY HEALTH INC 70,299 0.0204
ARKG 30 Mar 2021 Buy SGFY SIGNIFY HEALTH INC 8,938 0.0027
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.